XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jul. 02, 2023
Jun. 30, 2024
Jul. 02, 2023
EPS Numerator        
Income from continuing operations attributable to Pfizer Inc. common shareholders $ 24 $ 2,329 $ 3,144 $ 7,871
Discontinued operations––net of tax 17 (2) 12 (1)
Net income attributable to Pfizer Inc. common shareholders 41 2,327 3,156 7,870
EPS Numerator––Diluted        
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions 24 2,329 3,144 7,871
Discontinued operations––net of tax 17 (2) 12 (1)
Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 41 $ 2,327 $ 3,156 $ 7,870
EPS Denominator        
Weighted-average number of common shares outstanding––Basic (in shares) 5,666 5,646 5,662 5,640
Common-share equivalents (in shares) 29 67 35 80
Weighted-average number of common shares outstanding––Diluted (in shares) 5,696 5,713 5,696 5,720
Anti-dilutive common stock equivalents (in shares) 23 3 [1] 24 [1] 2 [1]
[1] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.